IBDEI14O ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18110,2)
 ;;=^5138331
 ;;^UTILITY(U,$J,358.3,18111,0)
 ;;=E11.3212^^88^909^23
 ;;^UTILITY(U,$J,358.3,18111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18111,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
 ;;^UTILITY(U,$J,358.3,18111,1,4,0)
 ;;=4^E11.3212
 ;;^UTILITY(U,$J,358.3,18111,2)
 ;;=^5138332
 ;;^UTILITY(U,$J,358.3,18112,0)
 ;;=E11.3213^^88^909^24
 ;;^UTILITY(U,$J,358.3,18112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18112,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
 ;;^UTILITY(U,$J,358.3,18112,1,4,0)
 ;;=4^E11.3213
 ;;^UTILITY(U,$J,358.3,18112,2)
 ;;=^5138333
 ;;^UTILITY(U,$J,358.3,18113,0)
 ;;=E11.40^^88^909^10
 ;;^UTILITY(U,$J,358.3,18113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18113,1,3,0)
 ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,18113,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,18113,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,18114,0)
 ;;=E11.51^^88^909^12
 ;;^UTILITY(U,$J,358.3,18114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18114,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,18114,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,18114,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,18115,0)
 ;;=E11.52^^88^909^11
 ;;^UTILITY(U,$J,358.3,18115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18115,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,18115,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,18115,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,18116,0)
 ;;=E11.620^^88^909^5
 ;;^UTILITY(U,$J,358.3,18116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18116,1,3,0)
 ;;=3^DM Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,18116,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,18116,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,18117,0)
 ;;=E11.36^^88^909^4
 ;;^UTILITY(U,$J,358.3,18117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18117,1,3,0)
 ;;=3^DM Type 2 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,18117,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,18117,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,18118,0)
 ;;=I10.^^88^910^1
 ;;^UTILITY(U,$J,358.3,18118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18118,1,3,0)
 ;;=3^Essential/Primary Hypertension
 ;;^UTILITY(U,$J,358.3,18118,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,18118,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,18119,0)
 ;;=I11.0^^88^910^12
 ;;^UTILITY(U,$J,358.3,18119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18119,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,18119,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,18119,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,18120,0)
 ;;=I11.9^^88^910^13
 ;;^UTILITY(U,$J,358.3,18120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18120,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,18120,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,18120,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,18121,0)
 ;;=I12.0^^88^910^5
 ;;^UTILITY(U,$J,358.3,18121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18121,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
 ;;^UTILITY(U,$J,358.3,18121,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,18121,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,18122,0)
 ;;=I12.9^^88^910^4
 ;;^UTILITY(U,$J,358.3,18122,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18122,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
 ;;^UTILITY(U,$J,358.3,18122,1,4,0)
 ;;=4^I12.9
